| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/07/2002 | WO2002017929A1 Treatment of urinary dysfunction |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017926A1 Pharmaceutical composition and method for treating hypogonadism |
| 03/07/2002 | WO2002017924A1 Method of treatment |
| 03/07/2002 | WO2002017923A1 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 03/07/2002 | WO2002017921A2 Paroxetine compositions and processes for making the same |
| 03/07/2002 | WO2002017920A2 Use of methylphenidate compounds to enhance memory |
| 03/07/2002 | WO2002017919A2 Use of threo-methylphenidate compounds to enhance memory |
| 03/07/2002 | WO2002017918A2 Sustained release formulations for growth hormone secretagogues |
| 03/07/2002 | WO2002017917A1 Manzamines for treatment of drug resistant infection |
| 03/07/2002 | WO2002017915A1 Benzylidene thiazolidinediones and their use as antimycotic agents |
| 03/07/2002 | WO2002017914A2 Fused pyrrolocarbazoles against inflammation |
| 03/07/2002 | WO2002017910A1 Agents for neutron capture therapy |
| 03/07/2002 | WO2002017909A1 A therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives |
| 03/07/2002 | WO2002017907A1 Method for enhanced delivery of oxybutynin and compositions thereof |
| 03/07/2002 | WO2002017906A1 Composition and method for treatment of hypertriglyceridemia |
| 03/07/2002 | WO2002017905A2 Treatment of burns |
| 03/07/2002 | WO2002017904A1 Use of asiatic acid or asiaticoside for treatment of cancer |
| 03/07/2002 | WO2002017901A2 Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
| 03/07/2002 | WO2002017900A2 Modulators of us28 (chemokines) for treating cytomegalovirus infections |
| 03/07/2002 | WO2002017899A2 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
| 03/07/2002 | WO2002017898A2 Compositions and methods for inducing vasorelaxation |
| 03/07/2002 | WO2002017897A2 Methods for treating tumors using sulfonyl compounds |
| 03/07/2002 | WO2002017896A2 Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid |
| 03/07/2002 | WO2002017895A2 Use of an aldosterone receptor antagonist to improve cognitive function |
| 03/07/2002 | WO2002017894A2 Pharmaceutical formulation of salmeterol and fluticasone propionate |
| 03/07/2002 | WO2002017893A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | WO2002017892A2 Water-dispersible encapsulated sterols |
| 03/07/2002 | WO2002017891A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency |
| 03/07/2002 | WO2002017890A2 Treatment of arthritis and compositions therefore containing a n-acylated-2-glucosamine derivative |
| 03/07/2002 | WO2002017889A1 Transdermal therapeutic system for releasing venlafaxine |
| 03/07/2002 | WO2002017887A1 Medicament for treating intestinal diseases |
| 03/07/2002 | WO2002017881A2 Transdermal pharmaceutical delivery composition |
| 03/07/2002 | WO2002017879A1 Palatable oral coenzyme q liquid |
| 03/07/2002 | WO2002017870A2 Clear antiperspirants and deodorants made with siloxane-based polyamides |
| 03/07/2002 | WO2002017863A1 Hair growers |
| 03/07/2002 | WO2002017858A2 Role of fosb in bone formation |
| 03/07/2002 | WO2002017855A2 Process for preparing pharmaceutical compositions for use with soft gelatin formulations |
| 03/07/2002 | WO2002017854A2 Cephalosporin antibiotics and prodrugs thereof |
| 03/07/2002 | WO2002017852A2 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| 03/07/2002 | WO2002017735A2 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| 03/07/2002 | WO2002017734A2 Materials and methods for the treatment or prevention of obesity |
| 03/07/2002 | WO2002017732A2 Efficient method for producing compositions enriched in anthocyanins |
| 03/07/2002 | WO2001097750A3 Method for producing an antiviral agent |
| 03/07/2002 | WO2001093802A3 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy |
| 03/07/2002 | WO2001090103A9 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 03/07/2002 | WO2001090096A3 Triterpenoid derivatives and their use as antiproliferative agents |
| 03/07/2002 | WO2001089571A3 Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives |
| 03/07/2002 | WO2001089474A3 O/w emulsion |
| 03/07/2002 | WO2001089457A3 Thrombopoietin mimetics |
| 03/07/2002 | WO2001087232A3 Allantoin-containing skin cream |
| 03/07/2002 | WO2001082867A3 A core formulation |
| 03/07/2002 | WO2001080810A9 Chondroitin synthase gene and methods of making and using same |
| 03/07/2002 | WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists |
| 03/07/2002 | WO2001070176A3 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light |
| 03/07/2002 | WO2001068122A3 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 03/07/2002 | WO2001068047A3 Preparation containing quinoxaline derivatives |
| 03/07/2002 | WO2001068033A3 Il-8 receptor antagonists |
| 03/07/2002 | WO2001066697A3 Serum free cultivation of primate embryonic stem cells |
| 03/07/2002 | WO2001066551A3 Azole compounds as therapeutic agents for fungal infections |
| 03/07/2002 | WO2001064678A3 Inhibitors of hepatitis c virus ns3 protease |
| 03/07/2002 | WO2001064226A3 Farnesyl protein transferase inhibitor combinations with platinum compounds |
| 03/07/2002 | WO2001064194A3 Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| 03/07/2002 | WO2001064187B1 Anaesthetic formulations |
| 03/07/2002 | WO2001062765A3 Small molecule modulators of g protein-coupled receptor six |
| 03/07/2002 | WO2001062258A3 Improvement of implantation rate using ff-mas |
| 03/07/2002 | WO2001062236A3 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 03/07/2002 | WO2001062227A3 Anticholinergic drug formulations for treatment of chronic obstr uctive pulmonary disease |
| 03/07/2002 | WO2001060983A3 Treatment for bone disorders |
| 03/07/2002 | WO2001060414A3 Genetic modification of the lung as a portal for gene delivery |
| 03/07/2002 | WO2001060407A3 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis |
| 03/07/2002 | WO2001058471A3 Novel amino acid and peptide inhibitors of staphylococcus virulence |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001056983A3 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| 03/07/2002 | WO2001056556A3 Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders |
| 03/07/2002 | WO2001055131A3 Prodigiosin-derivatives as neoplastic and anti-viral agents |
| 03/07/2002 | WO2001055092B1 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 03/07/2002 | WO2001054502A3 Concentrated solution of quaternary ammonium compounds and methods of use |
| 03/07/2002 | WO2001053493A3 Human kinase protein and polynucleotides encoding the same |
| 03/07/2002 | WO2001052896A3 Compositions with enhanced oral bioavailability |
| 03/07/2002 | WO2001052824A3 Use of particular compounds for prophylaxis and treatment of hepatitis c |
| 03/07/2002 | WO2001051040B1 Osmotic device containing alprazolam and an antipsychotic agent |
| 03/07/2002 | WO2001051028A3 Formulations and methods for administration of pharmacologically or biologically active compounds |
| 03/07/2002 | WO2001049261A3 Stable aqueous deoxyfructosazine solution |
| 03/07/2002 | WO2001046166A3 Partially saturated calcium channel blockers |
| 03/07/2002 | WO2001044271A3 Daptomycin analogs and their use as antibacterial agents |
| 03/07/2002 | WO2001043692A3 SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| 03/07/2002 | WO2001041758A3 Valnemulin formulation |
| 03/07/2002 | WO2001036686A3 Genomic polymorphism for predicting therapeutic response |
| 03/07/2002 | WO2001029218A3 Nuclear matrix proteins, polynucleotide sequences encoding them, and their use |
| 03/07/2002 | WO2001028591A3 Injection vehicle for polymer-based formulations |
| 03/07/2002 | WO2001024831A3 Polymer stabilized neuropeptides |
| 03/07/2002 | WO2001023377A3 Polymorphic salt |
| 03/07/2002 | WO2001021163A3 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/07/2002 | WO2001021162A3 Treating allergic and inflammatory conditions using desloratadine |
| 03/07/2002 | WO2001015673A3 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 03/07/2002 | WO2001011086A3 Methods of screening for angiogenesis modulators |
| 03/07/2002 | WO2001001974A3 Naaladase inhibitors in anxiety and memory disorders |
| 03/07/2002 | WO2000071571A8 Fap-activated anti-tumor compounds |
| 03/07/2002 | US20020029039 Supplemental spine fixation device and methods |